Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

This study is testing a combination of four drugs — belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone — in people with relapsed or refractory multiple myeloma (a blood cancer that has come back or stopped responding to treatment). Belantamab mafodotin is an antibody-drug conjugate that targets a protein called BCMA on myeloma cells. **You may be eligible if...** - You are 18 or older with multiple myeloma that has returned or stopped responding to previous treatments - Your life expectancy is more than 3 months - You are in reasonably good health (ECOG performance status ≤ 2) - Your organs are functioning adequately based on lab tests - You are using effective birth control if applicable **You may NOT be eligible if...** - Your multiple myeloma has never been treated - You have serious organ problems that would prevent you from tolerating this regimen - You are pregnant or breastfeeding - You have active, uncontrolled infections Talk to your doctor to see if this trial is right for you.